---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-281657"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:55:48.421207+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Q3: Phase 3 melanoma trial narrowly misses PFS endpoint; cash $30.7M, runway to Q1 2026

## Summary
- Phase 3 IOB-013 trial in advanced melanoma showed PFS improvement but narrowly missed statistical significance; FDA meeting in December for new registrational trial design.
- Q3 total operating expenses $19.4M, down from $26.5M YoY; R&D expenses $13.7M vs $20.2M prior year.
- Cash and equivalents $30.7M as of Sep 30, 2025, down from $60.0M at Dec 31, 2024; expects to fund operations through Q1 2026.
- Cash increased $2.5M in Q3 from €12.5M EIB loan drawdown and $6.6M net ATM proceeds.
- Pre-clinical data for pipeline candidates IO112 (arginase 1) and IO170 (TGF-β) presented at SITC.

## SEC filing metadata
- accession: 0001193125-25-281657
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312525281657/0001193125-25-281657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312525281657/d36523d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-281657
- JSON: https://secwatch.observer/filing/0001193125-25-281657.json
- Plain text: https://secwatch.observer/filing/0001193125-25-281657.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.